Bernard Gilly, GenSight CEO (Eric Piermont/AFP via Getty Images)
June 30, 2021 07:37 AM EDTUpdated 11:00 AM
R&D
Cell/Gene Tx

Gen­Sight's gene ther­a­py mys­tery con­tin­ues, as pa­tients im­prove in an­oth­er failed tri­al

Jason Mast

Editor

A three-year-old med­ical mys­tery took its lat­est turn Thurs­day, when Gen­Sight re­leased da­ta from its third tri­al for a rare form of blind­ness: Once again …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times